Increasing competition in molecular diagnostics
New entrants from biochemistry/ELISA are entering molecular diagnostics due to high margins, pressuring pricing and market share.
3BBLACKBIODX / bear-case history
Track the concerns that keep returning.
3B Blackbio DX · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
HAT contract sunset risk
The WHO HAT contract (~$1.5M/year) will end in ~2 years; replacement revenue from US FDA is uncertain.
Slow NGS adoption and low margins
NGS segment has low margins and slow traction; management views it as a technology hedge rather than a growth driver.
Credit period extension impacting cash flow
Industry credit periods have extended to 3-5 months, matching competitors, which could pressure working capital.